These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16931788)

  • 1. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
    Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
    Kooistra T; Verschuren L; de Vries-van der Weij J; Koenig W; Toet K; Princen HM; Kleemann R
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2322-30. PubMed ID: 16873727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
    van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
    Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
    van der Hoorn JW; Kleemann R; Havekes LM; Kooistra T; Princen HM; Jukema JW
    J Hypertens; 2007 Dec; 25(12):2454-62. PubMed ID: 17984667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
    Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
    Chira EC; McMillen TS; Wang S; Haw A; O'Brien KD; Wight TN; Chait A
    Atherosclerosis; 2007 Nov; 195(1):100-9. PubMed ID: 17214992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.
    Hartvigsen K; Binder CJ; Hansen LF; Rafia A; Juliano J; Hörkkö S; Steinberg D; Palinski W; Witztum JL; Li AC
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):878-85. PubMed ID: 17255537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.
    Raffai RL; Loeb SM; Weisgraber KH
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):436-41. PubMed ID: 15591220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
    Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH
    Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
    Hellmold H; Zhang H; Andersson U; Blomgren B; Holland T; Berg AL; Elebring M; Sjögren N; Bamberg K; Dahl B; Westerberg R; Dillner B; Tugwood J; Tugwood J; Roberts R; Lundholm E; Camejo G; Skånberg I; Evans J
    Toxicol Sci; 2007 Jul; 98(1):63-74. PubMed ID: 17468185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
    Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
    Sharma S; Sowjanya A; Kumari M; Suryaprakash R; Cynthia G; Suresh J; Chakrabarti R
    Life Sci; 2006 Dec; 80(3):235-44. PubMed ID: 17014868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
    Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
    Schuster H; Fagerberg B; Edwards S; Halmos T; Lopatynski J; Stender S; Birketvedt GS; Tonstad S; Gause-Nilsson I; Halldórsdóttir S; Ohman KP;
    Atherosclerosis; 2008 Mar; 197(1):355-62. PubMed ID: 17631296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis.
    Liu R; Hojjati MR; Devlin CM; Hansen IH; Jiang XC
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):190-6. PubMed ID: 17038631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.